AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38295954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 600 mg QD in phase 1/2
Number of subjects: 127
Study 38295954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505)
Number of subjects: 127
Study 38295968 — intervention group
Group type: EXPERIMENTAL
Intervention: Annovera (segesterone acetate and ethinyl estradiol ring)
Number of subjects: 2064
Study 38296197 — intervention group
Group type: COMPARATOR
Intervention: Dermatoscopy alone
Number of subjects: 1005
Study 38296197 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Reflectance Confocal Microscopy (RCM)
Number of subjects: 1005
Study 38296249 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter implants (6 mm)
Number of subjects: 101
Study 38296249 — intervention group
Group type: COMPARATOR
Intervention: Standard-length implants (11-15 mm) with sinus grafting
Number of subjects: 101
Study 38296269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field MRI (<0.5T)
Number of subjects: 300
Study 38296269 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuroimaging
Number of subjects: 300
Study 38296273 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol supplementation (one time per day for 8 weeks)
Number of subjects: 60
Study 38296273 — intervention group
Group type: COMPARATOR
Intervention: Clinician-prescribed treatment without polyphenols
Number of subjects: 60
Study 38296274 — intervention group
Group type: EXPERIMENTAL
Intervention: CB-PTSD and CB-PTSS prevalence
Number of subjects: 300
Study 38296274 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of CB-PTSD and CB-PTSS
Number of subjects: 300
Study 38296274 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of childbirth experience
Number of subjects: 300
Study 38296274 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and economic determinants
Number of subjects: 300
Study 38296279 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day and 6 months of androgen deprivation therapy
Number of subjects: 36
Study 38296283 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROM-based systematic symptom monitoring and management intervention (completed once a month for 6 months)
Number of subjects: 0
Study 38296283 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 38296290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate
Number of subjects: 90
Study 38296290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferric maltol
Number of subjects: 90
Study 38296290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 90
Study 38296293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate 4 mg two times a day for 6 months
Number of subjects: 80
Study 38296293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38296293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Number of subjects: 80
Study 38296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based motivational interviewing (MI-only arm)
Number of subjects: 0
Study 38296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based motivational interviewing with mobile breathalysers (MI-plus arm)
Number of subjects: 0
Study 38296300 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control arm)
Number of subjects: 0
Study 38296309 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 31
Study 38296309 — intervention group
Group type: COMPARATOR
Intervention: Sham transplantation
Number of subjects: 31
Study 38296588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rhPro-UK (35 mg)
Number of subjects: 1446
Study 38296588 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 1446
Study 38296589 — intervention group
Group type: EXPERIMENTAL
Intervention: Head dOwn-Position (HDP) -20° Trendelenburg plus standard medical care
Number of subjects: 600
Study 38296589 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 600
Study 38296630 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day)
Number of subjects: 521
Study 38296630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 38296630 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 521
Study 38296802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1252
Study 38296849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT pulmonary angiogram (CTPA) protocol
Number of subjects: 113
Study 38296965 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus DMF
Number of subjects: 713
Study 38296965 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 713
Study 38297196 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training in difficult airway management according to DAS guidelines
Number of subjects: 24
Study 38297196 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 24
Study 38297229 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR heart health tool for cancer survivors
Number of subjects: 502
Study 38297229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported CVH factors
Number of subjects: 502
Study 38297229 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based categorization of CVH factors
Number of subjects: 502
Study 38297266 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-administered anthropometric assessments (no-contact protocol)
Number of subjects: 76
Study 38297266 — intervention group
Group type: COMPARATOR
Intervention: Standard assessor-led protocol
Number of subjects: 76
Study 38297285 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrazygomatic (IZC) miniscrew-anchored Carriere Motion appliance (CMA)
Number of subjects: 32
Study 38297285 — intervention group
Group type: COMPARATOR
Intervention: Essix retainer-anchored Carriere Motion appliance (CMA)
Number of subjects: 32
Study 38297308 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-treated surfaces
Number of subjects: 0
Study 38297308 — intervention group
Group type: COMPARATOR
Intervention: Machined surfaces
Number of subjects: 0
Study 38297337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 200
Study 38297337 — intervention group
Group type: COMPARATOR
Intervention: Vi-PS vaccine (control)
Number of subjects: 200
Study 38297352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) alone
Number of subjects: 23
Study 38297352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) plus paclitaxel (PAC)
Number of subjects: 23
Study 38297397 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified colonoscopy with targeted sampling alone
Number of subjects: 1952
Study 38297397 — intervention group
Group type: COMPARATOR
Intervention: Standard of care high-definition white-light colonoscopy with 32 to 40 non-targeted biopsies of non-neoplastic-appearing mucosa along with a sampling of abnormal-appearing mucosa
Number of subjects: 1952
Study 38297399 — intervention group
Group type: EXPERIMENTAL
Intervention: FINGER 2.0 intervention (lifestyle + metformin if eligible)
Number of subjects: 600
Study 38297399 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice (control arm)
Number of subjects: 600
Study 38297399 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day or 1000 mg/day)
Number of subjects: 600
Study 38297399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 38297524 — intervention group
Group type: COMPARATOR
Intervention: Continue DMARDs at 100% dose
Number of subjects: 303
Study 38297524 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper DMARDs to 50% dose
Number of subjects: 303
Study 38297524 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop DMARDs after tapering to 50% dose for 6 months
Number of subjects: 303
Study 38297916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exebacase + antibiotics
Number of subjects: 259
Study 38297916 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 259
Study 38298058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (tablet/solution) administered twice daily (b.i.d.)
Number of subjects: 246
Study 38298058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral solution)
Number of subjects: 246
Study 38298125 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (50, 100, or 200 µg)
Number of subjects: 0
Study 38298125 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (100 µg)
Number of subjects: 0
Study 38298125 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (100 µg, 3 doses)
Number of subjects: 0
Study 38298125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38298420 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8-positive selection of CD22 CAR T cells
Number of subjects: 0
Study 38298420 — intervention group
Group type: COMPARATOR
Intervention: CD4/CD8-negative selection of CD22 CAR T cells
Number of subjects: 0
Study 38298510 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA radioligand therapy
Number of subjects: 23
Study 38298510 — intervention group
Group type: EXPERIMENTAL
Intervention: cGAP
Number of subjects: 23
Study 38298551 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-B) intervention for 10 minutes twice daily for 4 weeks using Polar H10 ECG and Elite HRV app
Number of subjects: 13
Study 38298551 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-B) intervention
Number of subjects: 13
Study 38298861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg) administered intravenously at weeks 0, 2, 6, then every 8 weeks for 26 or 52 weeks
Number of subjects: 27
Study 38299059 — intervention group
Group type: EXPERIMENTAL
Intervention: ATI-1777 topical solution
Number of subjects: 48
Study 38299059 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 48
Study 38299306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration intervention
Number of subjects: 38
Study 38299306 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study 38299334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (n=58)
Number of subjects: 120
Study 38299334 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (n=58)
Number of subjects: 120
Study 38299348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assessed internal jugular vein (JV) distensibility with a threshold of 1.6
Number of subjects: 201
Study 38299348 — intervention group
Group type: EXPERIMENTAL
Intervention: JV distensibility ratio >1.6
Number of subjects: 201
Study 38299348 — intervention group
Group type: COMPARATOR
Intervention: High JV distensibility ratio (>1.6)
Number of subjects: 201
Study 38299348 — intervention group
Group type: COMPARATOR
Intervention: Low JV distensibility ratio (≤1.6)
Number of subjects: 201
Study 38299363 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 698
Study 38299363 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 698
Study 38299416 — intervention group
Group type: COMPARATOR
Intervention: 400 IU cholecalciferol + placebo three times daily (Group I)
Number of subjects: 45
Study 38299416 — intervention group
Group type: COMPARATOR
Intervention: 600 mg curcumin + 15,800 mg piperine once daily and three times daily placebo (Group II)
Number of subjects: 45
Study 38299416 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol three times daily and 600 mg curcumin + 15,800 mg piperine once daily (Group III)
Number of subjects: 45
Study 38299468 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal stent implantation
Number of subjects: 63
Study 38299468 — intervention group
Group type: COMPARATOR
Intervention: Large-sized bare-metal coronary stent (BMCS) implantation
Number of subjects: 63
Study 38299514 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5F Mini Flexible Ureteroscope
Number of subjects: 0
Study 38299514 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38299539 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) at a dose of 160 mg QD given 3 days/week
Number of subjects: 0
Study 38299539 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) in combination with talazoparib, olaparib, niraparib, lunresertib, or gemcitabine
Number of subjects: 0
Study 38299539 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38299578 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone (Isa-Pd)
Number of subjects: 307
Study 38299578 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone (Pd)
Number of subjects: 307
Study 38299639 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin system (RAS) inhibition
Number of subjects: 4856
Study 38299639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy in addition to standard care
Number of subjects: 4856
Study 38299639 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy, fish oil, and traditional Chinese medicines
Number of subjects: 4856
Study 38299639 — intervention group
Group type: COMPARATOR
Intervention: Antimalarial therapy
Number of subjects: 4856
Study 38299667 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD74 expression
Number of subjects: 973
Study 38299667 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD74 therapy
Number of subjects: 973
Study 38300235 — intervention group
Group type: EXPERIMENTAL
Intervention: PP6M
Number of subjects: 178
Study 38300235 — intervention group
Group type: COMPARATOR
Intervention: PP3M
Number of subjects: 178
Study 38300235 — intervention group
Group type: COMPARATOR
Intervention: PP1M
Number of subjects: 178
Study 38300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry supplementation (single dose)
Number of subjects: 60
Study 38300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry supplementation (six weeks)
Number of subjects: 60
Study 38300292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (six weeks)
Number of subjects: 60
Study 38300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (both groups)
Number of subjects: 60
Study 38300339 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood samples from TN patients
Number of subjects: 0
Study 38300339 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 0
Study 38300339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway enrichment analysis
Number of subjects: 0
Study 38300339 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI network analysis
Number of subjects: 0
Study 38300341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-etoposide chemotherapy (200 mg pembrolizumab every 3 weeks, 75 mg cisplatin)
Number of subjects: 15
Study 38300341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-etoposide chemotherapy
Number of subjects: 15
Study 38300408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 113
Study 38300408 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab 100 mg
Number of subjects: 113
Study 38300408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg and Guselkumab 100 mg
Number of subjects: 113
Study 38300710 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + Pertuzumab (P)
Number of subjects: 129
Study 38300759 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Only
Number of subjects: 290
Study 38300759 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 + CBT
Number of subjects: 290
Study 38300759 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 290
Study 38300759 — intervention group
Group type: COMPARATOR
Intervention: CBT Only
Number of subjects: 290
Study 38300838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile tea (3 g in 150 mL water)
Number of subjects: 8
Study 38300838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule (500 mg)
Number of subjects: 8
Study 38301149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0
Study 38301149 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0
Study 38301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38301187 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OL)
Number of subjects: 1538
Study 38301187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 1538
Study 38301385 — intervention group
Group type: EXPERIMENTAL
Intervention: Revie ⊕ intervention
Number of subjects: 58
Study 38301418 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rounds for family engagement
Number of subjects: 52
Study 38301673 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 94
Study 38301673 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 94
Study 38301682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil withdrawal (tapered over 12 weeks)
Number of subjects: 102
Study 38301682 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil maintenance (1-3g per day for 60 weeks)
Number of subjects: 102
Study 38301682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil withdrawal
Number of subjects: 102
Study 38301682 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil maintenance
Number of subjects: 102
Study 38302093 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation (dosage and duration not specified)
Number of subjects: 0
Study 38302221 — intervention group
Group type: EXPERIMENTAL
Intervention: RVd/R (lenalidomide 25 mg orally on days 1-14; bortezomib 1.3 mg/m2)
Number of subjects: 564
Study 38302221 — intervention group
Group type: EXPERIMENTAL
Intervention: RVd/E-R
Number of subjects: 564
Study 38302221 — intervention group
Group type: EXPERIMENTAL
Intervention: E-RVd/R
Number of subjects: 564
Study 38302221 — intervention group
Group type: EXPERIMENTAL
Intervention: E-RVd/E-R
Number of subjects: 564
Study 38302281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based car restraint educational intervention using Computer Intervention Authoring Software (CIAS)
Number of subjects: 211
Study 38302281 — intervention group
Group type: COMPARATOR
Intervention: Printed handouts on car restraint safety (Control)
Number of subjects: 211
Study 38302299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Number of subjects: 72
Study 38302299 — intervention group
Group type: COMPARATOR
Intervention: Patient education brochure
Number of subjects: 72
Study 38302476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (starting at 60 mg/m²); duration not specified.
Number of subjects: 0
Study 38302476 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab; duration not specified.
Number of subjects: 0
Study 38302483 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension exercises
Number of subjects: 56
Study 38302483 — intervention group
Group type: COMPARATOR
Intervention: Flexion exercises
Number of subjects: 56
Study 38302715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab (1,200 mg) plus chemotherapy (cisplatin 80 mg)
Number of subjects: 540
Study 38302715 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin 80 mg)
Number of subjects: 540
Study 38302718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 907
Study 38302718 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 907
Study 38302725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks (≤35 cycles)
Number of subjects: 155
Study 38302725 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice chemotherapy (TPC)
Number of subjects: 155
Study 38302725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib+pembrolizumab
Number of subjects: 155
Study 38302765 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (open-label trial)
Number of subjects: 1044
Study 38302765 — intervention group
Group type: COMPARATOR
Intervention: Daridorexant (phase III trial)
Number of subjects: 1044
Study 38302850 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) model for pneumonia diagnosis on chest x-ray (CXR)
Number of subjects: 430
Study 38302850 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists reviewing CXR
Number of subjects: 430
Study 38302850 — intervention group
Group type: COMPARATOR
Intervention: Emergency physicians reviewing CXR
Number of subjects: 430
Study 38302850 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT) for pneumonia diagnosis
Number of subjects: 430
Study 38302933 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-1, 4 cycles of 7.4 GBq
Number of subjects: 48
Study 38302936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics assessment including clinical characteristics, laboratory testing, imaging, Kansas City Cardiomyopathy Questionnaire (KCCQ), Physical Activity Scale of the Elderly (PASE), and cardiopulmonary exercise testing (CPET).
Number of subjects: 691
Study 38302990 — intervention group
Group type: EXPERIMENTAL
Intervention: MED-amplified dietary pattern (500 kcal/day from eight MED target foods: avocado, basil, cherry, chickpea, oat, red bell pepper, walnut, and alternating protein source of salmon or unprocessed, lean beef)
Number of subjects: 0
Study 38302990 — intervention group
Group type: COMPARATOR
Intervention: Habitual/Western dietary pattern (500 kcal/day from six non-MED target foods: cheesecake, chocolate frozen yogurt, refined grain bread, sour cream, white potato, and unprocessed, lean beef)
Number of subjects: 0
Study 38302990 — intervention group
Group type: EXPERIMENTAL
Intervention: MED-amplified dietary pattern
Number of subjects: 0